Investigating Medication vs. Prostatic Urethral Lift: Assessment and Comparison of Therapies for BPH
Status:
Not yet recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
This prospective, multicenter, two-arm, 1:1 randomized controlled trial (RCT) will enroll
approximately 250 males at approximately 25 sites located within the United States. All
enrolled subjects will be 45 years of age or older diagnosed with symptomatic benign
prostatic hyperplasia (BPH). They will be randomized to one of two readily available,
marketed BPH therapies; Prostatic Urethral Lift procedure with the UroLift System (PUL Arm)
or 0.4mg tamsulosin HCl (MED Arm).